Relmada Therapeutics – LaidLaw Capital Markets

Skip to content

Home
Healthcare Investment Banking
Institutional Sales
Laidlaw Ventures
Research
- Research Coverage List
Trading
Contact Us
Laidlaw & Company

Previous Next

Relmada
Therapeutics
admin2018-05-04T16:12:06+00:00

Project Description

Convertible
Preferred Stock
& Warrants

$8,000,000

Placement Agent
September 2013

Site Info

Home
Contact Us
History of Company

Legal

Terms & Conditions
Legal Information
Privacy Policy
Glossary

Disclosures

FINRA
SIPC
FCA
Business Continuity Plan Disclosure
SEC Order Routing Disclosure
Brokercheck

Laidlaw & Company (UK) Ltd., FINRA a broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw, through its clearing firm, acts on behalf of UK and European Union investors through Laidlaw & Company International Limited, its sister company, authorised by the Financial Conduct Authority (FCA) in the UK (Ref No: 537165).

Copyright 2017 Laidlaw & Company (UK) Ltd. - All Rights Reserved.

Toggle Sliding Bar Area

Research Coverage List
Research Overview